Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma

NEW YORK--(BUSINESS WIRE)--Summary: Helsinn Healthcare SA and Zealand Pharma A/S today announced that it has signed a partnering agreement, for the development and worldwide commercialization of Zealand’s ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.